Action ALRN AILERON THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Aileron Therapeutics, Inc.

Actions

ALRN

US00887A2042

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 17/07/2024 		Varia. 5j. Varia. 1 janv.
2,99 USD -3,24 % Graphique intraday de Aileron Therapeutics, Inc. -2,29 % -1,92 %
16/05 Aileron Therapeutics, Inc. annonce des changements au sein de sa direction CI
15/05 Aileron Therapeutics, Inc. annonce ses résultats pour le premier trimestre terminé le 31 mars 2024 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Aileron Therapeutics to be Included in the Russell Microcap® Index
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Index
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Index
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell Microcap Growth Index
Aileron Therapeutics, Inc.(NasdaqCM:ALRN) added to Russell 3000E Growth Index
Certain Warrants of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
Certain Common Stock of Aileron Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 18-JUN-2024.
Aileron Therapeutics, Inc. Announces Chief Financial Officer Changes
Aileron Therapeutics, Inc. Announces Executive Changes
Aileron Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
Aileron Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Aileron Therapeutics to Present at Two Upcoming Investor Conferences
Aileron Therapeutics Closes Direct Offering of Shares, Warrants
Aileron Therapeutics Announces Closing of Underwritten Registered Direct Offering of up to Approximately $40 Million
Aileron Therapeutics Announces Pricing of Underwritten Registered Direct Offering Priced At-The-Market Under Nasdaq Rules of up to Approximately $40 Million
Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)
Aileron Therapeutics, Inc. Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis
Aileron Therapeutics : Corporate Presentation April 2024
Aileron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aileron Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ALRN
  4. Actualités Aileron Therapeutics, Inc.
  5. Autres langues